{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:17:48Z","timestamp":1782379068916,"version":"3.54.5"},"reference-count":36,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Ther. Deliv."],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.4155\/tde-2018-0006","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T09:31:52Z","timestamp":1530005512000},"page":"547-556","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["ILUVIEN\n            <sup>\u00ae<\/sup>\n            Technology in the Treatment of center-involving Diabetic Macular edema: a Review of the Literature"],"prefix":"10.1080","volume":"9","author":[{"given":"Maged S","family":"Habib","sequence":"first","affiliation":[{"name":"Consultant Ophthalmologist, Sunderland Eye InfirmaryQueen Alexandra RoadSunderlandSR2 9HPUK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000726"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3701-4-27"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.03.033"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488712799363299"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399810666140402123026"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.014"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.06.015"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.024"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-015-0029-z"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.048"},{"key":"e_1_3_5_13_1","article-title":"Sustained-release corticosteroid delivery systems\u2013implant technology offers promising solutions to the burden of repeated injections for retinal diseases","volume":"44","author":"Kiss S","year":"2010","unstructured":"Kiss S . Sustained-release corticosteroid delivery systems\u2013implant technology offers promising solutions to the burden of repeated injections for retinal diseases. Retin. Today, May\/June, 44\u201346 (2010).","journal-title":"Retin. Today"},{"key":"e_1_3_5_14_1","unstructured":"Medicines and Healthcare products Regulatory Agency Public assessment report mutual recognition procedure - ILUVIEN 190 micrograms intravitreal implant in applicator. www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con171936.pdf."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0100"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.028"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.030"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.98"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.11.034"},{"issue":"8","key":"e_1_3_5_20_1","first-page":"915","article-title":"Early versus long-term changes in visual acuity (VA) with continuous 0.2 $\u03bc$g\/day fluocinolone acetonide (FAc) microdosing","volume":"58","author":"John VJ","year":"2017","unstructured":"John VJ . Early versus long-term changes in visual acuity (VA) with continuous 0.2 $\u03bc$g\/day fluocinolone acetonide (FAc) microdosing. Invest. Ophthalmol. Vis. Sci.58 (8), 915 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_5_21_1","unstructured":"Chakravarthy U Taylor S Bailey C Koch F Souza J . ILUVIEN (190micrograms fluocinolone acetonide) real-life safety and effectiveness following usage in three European countries\u2013results from the 2016 extract of data from the ILUVIEN Registry Safety Study (IRISS) (free paper). European Society of Retina Specialists (2017). www.euretina.org\/barcelona2017\/programme\/free-papers-details.asp?id=13188&day=0."},{"key":"e_1_3_5_22_1","unstructured":"Hillen M . The Chronic\u2013IRISS registry 24-month data shows when it comes to DME there's chronic and then there's chronic\u2013and treatment outcomes differ accordingly. Ophthalmol. (2017). https:\/\/the ophthalmologist.com\/issues\/1017\/the-chronic."},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.125"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.17925\/EOR.2015.09.01.42"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.303"},{"issue":"8","key":"e_1_3_5_26_1","first-page":"928","article-title":"The first European report of real-life clinical outcomes after 3 years of treatment with ILUVIEN\u00ae (fluocinolone acetonide) in patients with chronic diabetic macular edema (DME)","volume":"58","author":"Augustin AJ","year":"2017","unstructured":"Augustin AJ Atorf J . The first European report of real-life clinical outcomes after 3 years of treatment with ILUVIEN\u00ae (fluocinolone acetonide) in patients with chronic diabetic macular edema (DME). Invest. Ophthalmol. Vis. Sci.58 (8), 928 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_5_27_1","unstructured":"NICE . Technology appraisal guidance [TA301]. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (2013). https:\/\/www.nice.org.uk\/guidance\/ta301."},{"key":"e_1_3_5_28_1","unstructured":"ILUVIEN 190 micrograms intravitreal implant in applicator\u2013summary of product characteristics (SPC)\u2013(eMC). www.medicines.org.uk\/emc\/medicine\/27636."},{"key":"e_1_3_5_29_1","unstructured":"Retina Times . Three pillars of success in patient and practice management strategies in diabetic macular edema (2016). http:\/\/retinatoday.com\/pdfs\/0816_insert.pdf."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-015-0035-1"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000284"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1909"},{"key":"e_1_3_5_33_1","unstructured":"Royal National Institute of Blind People (UK) . Sight loss UK 2013 The latest evidence (2013). www.rnib.org.uk\/sites\/default\/files\/sight_loss_UK_2013.pdf."},{"issue":"1","key":"e_1_3_5_34_1","first-page":"e155","article-title":"Cost advantage of fluocinolone acetonide implant (ILUVIEN\u00ae) versus ranibizumab in the treatment of chronic diabetic macular oedema","volume":"4","author":"Quhill F","year":"2017","unstructured":"Quhill F Beiderbeck A . Cost advantage of fluocinolone acetonide implant (ILUVIEN\u00ae) versus ranibizumab in the treatment of chronic diabetic macular oedema. Glob. Reg. Heal. Technol. Assess.4 (1), e155\u2013e164 (2017).","journal-title":"Glob. Reg. Heal. Technol. Assess."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.11.041"},{"issue":"4","key":"e_1_3_5_36_1","first-page":"S63","article-title":"Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study","volume":"21","author":"Cutino A","year":"2015","unstructured":"Cutino A Green K Kendall R Moore PT Zachary C . Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study. Am. J. Manag. Care21 (Supp. 4), S63\u2013S72 (2015).","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S100168"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2017.1285698"}],"container-title":["Therapeutic Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/tde-2018-0006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:36:17Z","timestamp":1715963777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/tde-2018-0006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.4155\/tde-2018-0006"],"URL":"https:\/\/doi.org\/10.4155\/tde-2018-0006","relation":{},"ISSN":["2041-5990","2041-6008"],"issn-type":[{"value":"2041-5990","type":"print"},{"value":"2041-6008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}